在多发性硬化症下皮下使用ocrelizumab:第一阶段OCARINA I研究的结果
Scott D Newsome1, Lawrence Goldstick2, Derrick S Robertson3
1Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Annals of clinical and translational neurology
|October 26, 2024
概括
皮下使用的ocrelizumab为多发性硬化症 (MS) 提供了一种新的治疗选择. 这一1b期研究证实了它的安全性和耐受性,并选择了920毫克的剂量进行进一步的试验.
科学领域:
- 神经免疫学 神经免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 奥克雷利祖马布是多发性硬化症 (MS) 的一项成熟治疗方法.
- 目前正在开发一种皮下配方,以提高患者的方便性和治疗灵活性.
研究的目的:
- 评估皮下注射ocrelizumab的药理动力学,安全性,耐受性和免疫性.
- 为了确定第三阶段研究 (OCARINA II) 的最佳剂量.
主要方法:
- 第1b期,开放标签,剂量确定研究 (OCARINA I) 涉及复发性或初级进展性MS患者.
- 单次上升剂量的皮下用ocrelizumab被管理.
- 药理动力学和安全性数据决定了剂量选择,一些患者被随机分配,以比较皮下和静脉注射ocrelizumab.
主要成果:
- 在135名患者的所有测试剂量中,皮下用ocrelizumab的耐受性良好.
- 药物动力学和安全性概况支持选择920毫克的皮下剂量.
- 该研究成功确定了第三阶段试验的候选剂量.
结论:
- 皮下使用的ocrelizumab显示出良好的安全性和耐受性.
- 这种配方代表了多发性硬化症患者有前途的替代治疗选择.
- 进一步的第三阶段调查是有必要的.
相关概念视频
Clinical Trials
6.6K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.6K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143
Clinical Trials: Overview
2.8K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.8K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
97
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
97
Preclinical Development: Overview
4.3K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.3K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


